BMG Pharma is an Italian company, founded in 2018 from the merger between BMG Pharma S.r.l. and Sigea S.r.l, a spin-ff of the University of Trieste
BMGPharma is specialized in bio-polymers and macro-molecules from which a new-generation of Hyaluronic Acid derivatives (Hyaluromimethic) has been developed, based on proprietary technology.
The company operates on a B2B business model for in-partnership development, registration and commercialization of products for dermo-aesthetics, oral-nasal, gynecology and nutraceuticals applications.
BMG Pharma is conducting clinical trials to obtain EU registration of different Hyaluromimethic formulations, for application as fillers in dermatology, orthopedics and ophthalmology